The basic helix-loop-helix (bHLH) -PAS domain containing transcription factors CLOCK and BMAL1 are two major components of the circadian molecular oscillator. It is known that the CLOCK/BMAL1 complex positively regulates the activity of E-box containing promoters. Here we demonstrate that the CLOCK/BMAL1 complex can also suppress the activity of some promoters upon its interaction with CRYPTOCHROME (CRY). Such a dual function of the circadian transcriptional complex provides a mechanistic explanation for the unpredicted pattern of circadian gene expression in the tissues of Bmal1 null mice. We speculate that the switch from transcriptional activation to transcriptional repression may provide a highly efficient mechanism for circadian control of gene expression. We also show that CLOCK/BMAL1 can interfere with promoter regulation by other, non-circadian, transcription factors including N-MYC and ETS, leading to attenuation or abrogation of transcription of CLOCK/BMAL1-controlled stressinduced genes. We propose that, based upon these results, both circadian repression and activation of the transcription of different target genes are required for circadian responses to various external stimuli, including genotoxic stress induced by anticancer treatment.
In addition to generating normal daily physiological variations, the circadian clock system has also been implicated in modulation of various pathological conditions. It has been reported that the acute phases of various diseases have strong circadian components. Thus, the welldocumented phenomenon of increased death from heart disease in the early hours of the morning have been attributed to daily variations in blood pressure, heart rate and cardiac output (5) (6) (7) . In addition, asthmatic attacks are reported to occur more frequently at nighttime, probably due to a nocturnal increase in airway inflammation and bronchial responsiveness [reviewed in (8) ]. The circadian system is also involved in modulation of responses to different types of anti-cancer therapies (9, 10) .
Recently, by using circadian mutant mice deficient in different components of the molecular clock system, we have demonstrated that daily variations in the sensitivity of normal cells and tissues to genotoxic stress induced by anticancer therapy correlate with CLOCK/BMAL1 transcriptional activity (11) . Thus, animals deficient in transcriptional activators (Clock/Clock mutant and Bmal1 −/− knockout mice) are more sensitive to toxicity induced by the widely used chemotherapeutic drug cyclophosphamide, while animals deficient in transcriptional repressors (Cry1 −/− Cry2 −/− knockout mice) are more resistant. Based on these results, we hypothesize that the circadian clock modulates in vivo responses through CLOCK/BMAL1-dependent control of the balance of pro-death/pro-survival genes and that the expression of these genes will correlate with the functional status of CLOCK/BMAL1. Thus, it is expected that genes that are downregulated in the tissues of Clock/Clock and Bmal1 −/− mice, will be up-regulated in the tissues of
To test this prediction, we determined temporal expression profiles for several well-characterized transcriptional targets of the CLOCK/BMAL1 complex in wild-type, Clock/Clock, Bmal1 −/− and Cry1 −/− Cry2 −/− animals. Surprisingly, some transcriptional targets of the CLOCK/BMAL1 complex demonstrate unpredicted expression profiles in peripheral tissues of Bmal1 −/− mice that cannot be explained by the existing model of circadian transcriptional regulation. Thus, in Bmal1 −/− mice, some genes (such as Per1) were down-regulated as in Clock/Clock mice, while
other genes (such as Cry1) were up-regulated as in Cry1 −/− Cry2 −/− mice. Direct comparison of the CLOCK/BMAL1/CRY1-mediated regulation of Per1 and Cry1 promoters in transient transfection experiments, demonstrated that these two promoters are regulated by different mechanisms: Per1 is controlled primarily by transactivation, while Cry1 is controlled mainly by transrepression. Taken together, these data suggest that the CLOCK/BMAL1 complex may function both as transcriptional activator and transcriptional repressor, and that the switch from activation to repression depends upon CLOCK/BMAL1 interaction with CRY. We also demonstrate that CLOCK/BMAL1/CRY1-mediated repression interferes with the activation of target genes by other transcriptional factors and hypothesize that this type of regulation may provide a more efficient and important means for circadian control of stress responses than would be provided by daily variations in mRNA levels alone. We propose, based upon these results, a model of functional interplay between circadian and stress response pathways, which provides a mechanistic explanation for daily variations in stress responses. 
MATERIALS AND METHODS

Animals and tissue collection
RNA isolation and real-time PCR analysis
Total RNA was isolated from tissue samples with TriZol reagent (Invitrogen) according to the manufacturer's protocol. RNA quantitation was performed using TaqMan real-time RT-PCR as described previously (15) using the following primers/probes sets:
ACG CCG TG-3′ and 5′-CGT TCT AGA TCA GTT ACT GCT CTG CCG-3′ and re-cloned into Sal I +Xba I digested pCMV-BD. Similarly, full-length Per2 was amplified from pCMV-Per2 using the oligonucleotides 5′-GAA AGA TCT AAT GGA TAC GTG GAC-3′ and 5′-GAA CTC GAG TTA CGT CTG GGC CTC-3′ and re-cloned into BamH I + Sal I digested pCMV-AD.
Transient transfection and luciferase reporter assay
HEK 293 cells were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum and 100 U/ml of penicillin and streptomycin. Typically cells were transfected in 6-well plates with the indicated amount of plasmid DNA (the final DNA amount was adjusted to 1000 ng with pcDNA3 vector) using LipofectAMINE PLUS reagents (Invitrogen) according to the manufacturer's protocol. 1 ng of pcDNA3-βGal was included for the normalization of transfection efficiency. Cells were collected for analysis 36 h after transfection. Luciferase activity was detected with Luciferase Assay System (Promega) according to manufacturer's protocol. Luminescence intensity was measured using Victor2 Wallac multichannel reader (Perkin Elmer). , and Cry1 −/− Cry2 −/− animals ( Fig. 1 ). As expected, in the livers of wildtype animals, all tested genes displayed 24 h oscillations in mRNA abundance with a phase similar to that previously reported (21) . All of the mutants deficient in different core components of the molecular oscillator (Clock/Clock, Bmal1 −/− , and Cry1 −/− Cry2 −/− ), demonstrate the disruption of the circadian profile of gene expression, though, the pattern of the change was different. Thus, consistent with our prediction, in the livers of Clock/Clock mutant mice, which are deficient in circadian transactivation function, target genes were either down-regulated (Per1, Dbp) or displayed median expression levels (Cry1, Fig. 1A ). Also consistent with our expectations, Per1 and Cry1 expression was up-regulated in the livers of Cry1 −/− Cry2 −/− double knockout animals lacking the CRY circadian repressor molecules (Fig. 1B) . In contrast, the expression patterns of the same target genes in the livers of Bmal1 −/− animals did not completely fit our original prediction. Thus, while the levels of Dbp, Per1 and Cry2 mRNAs were significantly decreased as expected ( Fig. 1C and data not shown); the levels of Cry1 mRNA were considerably increased (Fig. 1C) . Similar changes were detected in other peripheral tissue tested -salivary gland (data not shown).
RESULTS
Unpredicted
The comparison of the average levels of expression of CLOCK/BMAL1 transcriptional targets throughout the circadian cycle between all four genotypes confirmed that in Clock/Clock and Cry1 −/− Cry2 −/− mice the levels of all target genes analyzed changed as predicted. However, in peripheral tissues of Bmal1 −/− mice some genes were down-regulated as expected (Per1, Dbp and Rev-erb α) while others were up-regulated (Cry1) (Fig. 1D) . Thus, even though the Cry1 gene is a direct transcriptional target of CLOCK/BMAL1 (17, 18) and BMAL1 has been
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characterized as transcriptional activator, we find that BMAL1-deficiency results in an elevated level of Cry1 mRNA in peripheral tissues throughout the circadian cycle. This pattern is more consistent with the "lack of repression" effect characteristic of gene expression profiles in Cry1 −/− Cry2 −/− mice than of the "lack of activation" effect observed in Clock mutant mice and expected for Bmal1 −/− mutants (Fig. 1B) . These observations led us to hypothesize that BMAL1 might possess dual functional activity, acting as a transcriptional activator for some genes and a transcriptional repressor for others, even in the same tissue.
The CLOCK/BMAL1 complex represses the activity of the Cry1 promoter upon interaction with CRY
To test the hypothesis that CLOCK/BMAL1 activates some promoters while repressing others, we compared regulation of the isolated Per1 (down-regulated in peripheral tissues of Bmal1 −/− mice) and Cry1 (up-regulated in Bmal1 −/− mice) promoters in a cell culture system. HEK 293 cells were transiently transfected with reporter constructs containing the luciferase gene under the control of either the Per1 or Cry1 promoter and different combinations of CLOCK, BMAL1 and CRY1 expression constructs.
As expected, both promoters were induced by CLOCK/BMAL1 coexpression ( Fig. 2A) ; however, the fold of activation was different. While the Per1 promoter was induced more than 20-fold from its basal expression level, the Cry1 promoter, which displayed ~15-fold higher basal activity, was induced by CLOCK/BMAL1 only twofold. At the same time, expression of CRY1 inhibits CLOCK/BMAL1-dependent transactivation of the Per1 promoter to a level that is still higher than the basal activity; while on the Cry1 promoter, CRY1 expression results in very strong promoter repression (~3-fold lower than the basal). As a result, both promoters demonstrate similar change in the amplitude between their activated and repressed states (6-10 fold, depending on the levels of CLOCK, BMAL1 and CRY1 used in transfection); however, the same effect is achieved through different mechanisms. In the case of the Per1 promoter, it is based mainly on CLOCK/BMAL1-dependent transactivation, while in the case of the Cry1 it is based on CRY-mediated repression. Importantly, the presence of both CLOCK and BMAL1 was crucial for the repression of Cry1 promoter because CRY1 alone, CLOCK/CRY1 or BMAL1/CRY1 combinations were not efficient in promoter suppression (Fig. 2B ). These results demonstrate that CLOCK/BMAL1 is converted from transcriptional activator to transcriptional repressor by the presence of CRY1 protein.
The proposed dual functional role of the major circadian CLOCK/BMAL1 complex also implies that deficiency in CLOCK function should affect gene expression in the same way as deficiency in BMAL1. This, however, is not what was observed in our analysis of Clock/Clock mice (Fig. 1) . To estimate the effect of Clock mutation on transrepressor activity of the complex, we tested the ability of CLOCK Δ19 truncated protein, which contains the mutation present in Clock/Clock mice (22) , to suppress Cry1 promoter either by itself or in combination with BMAL1 and CRY1 proteins. As shown in Fig. 2C , CLOCK Δ19, which is deficient in transactivation function (16) and therefore cannot induce Cry1 promoter, still displays repressor properties upon CRY1 co-expression on Cry1 promoter (Fig. 2C) .
Thus, it is clear that the mutation present in Clock/Clock mice does not abrogate all of its functions and CLOCK Δ19 lost its transactivator, but not transrepressor properties.
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The molecular mechanism of CRY-mediated repression Although CRYs have been described as the inhibitors of CLOCK/BMAL1-mediated transcription, the exact molecular mechanism of their repressor function has not been determined yet. The most straightforward explanation might suggest that CRYs perform their repressor function through recruitment of a transcriptional repressor or that CRYs themselves act as active repressors that are targeted to promoters by the CLOCK/BMAL1 complex. If the latter case is true, targeting of CRYs to different promoters should result in their repression. To explore this hypothesis, we fused CRY1 with the DNA binding domain (BD) of the yeast GAL4 protein and showed that, similar to wild-type CRY1, the BD-CRY1 fusion protein efficiently inhibited the transactivation function of the CLOCK/BMAL1 complex (Fig. 3A) . When BD-CRY1 was coexpressed with a luciferase reporter under the control of a promoter containing a GAL4 responsive element (GRE), it had no effect on either the basal or induced activities of the promoter (the GRE promoter was induced by co-transfection with BD-p53/AD-large T-antigen expression constructs, Fig. 3B ). To control for BD-CRY1 binding to the GRE, we co-expressed it with PER2 fused to the transactivation domain (AD) of the p65 subunit of the transcriptional factor NFκB. Since CRY1 and PER2 interact with each other (19, 23) , this results in a BD-CRY1/AD-PER2 complex that contains both DNA binding and transactivation domains. We found that this complex could activate transcription of the GRE-containing reporter (Fig. 3C) , suggesting that it is unlikely that CRY1 is recruiting an active repressor or it acts as a repressor itself. Therefore, the results of our transient transfection experiments, together with the observed unusual patterns of CLOCK/BMAL1 target gene expression in Bmal1 −/− mice, cannot be explained within the framework of the current model of CRY-mediated repression (17) but are consistent with our proposed mechanism of a dual functional role for the circadian transcriptional complex.
The CLOCK/BMAL1/CRY1 complex interferes with the activity of other transcription factors
If the CLOCK/BMAL1/CRY1 complex indeed functions as an active transcriptional repressor, then it may interfere with the ability of other transcriptional factors to regulate the same promoter. Both the Per1 and Cry1 promoters contain recognition sites for various transcription factors, the combination of which determines both the basal level of gene expression and the level of induction under various conditions. For example, the difference in the basal activity of the Per1 and Cry1 promoters detected in our transient transfection experiments (Fig. 1A ) may reflect the fact that HEK293 cells express more Cry1-specific transcription factors. In this case, the Cry1 promoter would be constitutively active and additional activation by CLOCK/BMAL1 would have only a modest effect. At the same time, the Per1 promoter is largely inactive in these cells and expression of CLOCK/BMAL1 results in its strong activation.
To test whether the circadian transcriptional complex interacts with other regulatory elements on the same promoter, we analyzed the effect of the CLOCK/BMAL1/CRY1 complex on the ability of the non-circadian transcription factors N-MYC and ETS to activate the Cry1 promoter in a transient transfection/reporter construct system. As shown in Fig. 4 , either N-MYC or ETS expression leads to promoter activation and CLOCK/BMAL1 cooperates with these transcription factors, leading to even higher levels of activation. Co-expression of CRY1 alone has no effect on Cry1 transactivation induced by N-MYC and ETS; however, co-expression of the CLOCK/BMAL1/CRY1 complex has a strong inhibitory effect. Thus, CLOCK/BMAL1/CRY1 
DISCUSSION
The existing model of mammalian circadian transcriptional regulation is based on periodic activation/repression of numerous genes that are controlled by the activity of the CLOCK/BMAL1 transactivation complex. CLOCK/BMAL1-dependent transactivation, in turn, is inhibited by CRYPTOCHROME molecules through a yet unknown mechanism. The results of the transient transfection experiments presented here suggest that CRYs themselves do not act as transcriptional inhibitors but execute their repressor function by converting the CLOCK/BMAL1 complex from a transcriptional activator to a transcriptional repressor. This conclusion is also supported by the observed unusual patterns of expression of some circadian genes in peripheral tissues of Bmal1 −/− mice. This pattern is more consistent with the "lack of repression" effect characteristic of gene expression profiles in tissues of animals deficient in transcriptional repressors (Cry1 −/− Cry2 −/− mice) than of the "lack of activation" effect observed in Clock mutant mice and expected for Bmal1 −/− mutants. Although, we cannot completely rule out the possibility that such unusual gene expression profiles result from indirect compensatory mechanisms (for example, through the up-regulation of other functional partners of CLOCK, like MOP9 (24)), we think that in combination with the ability of circadian transcriptional complex to actively repress responsive promoters in transient transfection system, the model of active circadian repression provides more reasonable explanation.
The dual functional role of the circadian transcriptional complex that is proposed here allows for introducing some important modifications to the current view of the molecular mechanism of circadian transcriptional control in mammals. The presently accepted model suggests that the activation of circadian gene expression occurs through the CLOCK/BMAL1-dependent recruitment of histone acetyl-transferase (HAT) to specific promoter regions with periodic disruption of CLOCK/BMAL1 interaction with HAT by CRYs (17). However, this mode of regulation can be effective only in situations in which target genes are controlled exclusively by circadian transcription factors and in which basal promoter activity in the absence of transcriptionally active CLOCK/BMAL1 is low (Fig. 5A) . In reality, the promoter regions of many clock-controlled genes contain multiple regulatory elements for other factors that may also recruit HAT and keep the promoter constitutively active. In these cases, basal promoter activity will be high and additional circadian activation will not induce significant changes in expression (Fig. 5B ). On these types of promoters, daily oscillations in gene expression levels of significant amplitude can be achieved through the proposed repressor function of CLOCK/BMAL1/CRY1 (Fig. 5C) as illustrated by the example of Cry1 promoter regulation in our study.
In addition, while the current model cannot explain the observed unpredicted patterns of expression of CLOCK/BMAL1 target genes in some tissues of Bmal1 −/− animals, the proposed circadian repressor model provides a feasible explanation for this phenomenon. Based on our model, all CLOCK/BMAL1 target genes can be separated into two groups: (i) genes that are controlled exclusively by the CLOCK/BMAL1 circadian complex and, therefore, are regulated predominantly by transactivation; these genes are down-regulated in Bmal1 null mice (Dbp in the liver, Rev-erbα in salivary gland); and (ii) genes that are controlled by multiple factors, which keep them constitutively active; these genes are efficiently regulated by repression and are up-regulated upon Bmal1 disruption (Cry1 in the liver and salivary glands). Many genes may display an intermediate type of regulation (Per1 in the liver and salivary gland); in the tissues of Bmal1 −/− animals these genes will be up-regulated at the time when the circadian complex displays repressor properties and down-regulated when the complex functions as a transactivator.
Interestingly, the Clock mutation and the deletion of Bmal1 have different impacts on promoter activity and expression of target genes. Direct targets of CLOCK/BMAL1 that are regulated primarily by transactivation (such as Per2, Dbp, Rev-Erbα), are down-regulated in both Clock/Clock and Bmal1 −/− mice (Fig. 1) . On the other hand, genes that are regulated primarily by repression (such as Cry1) are up-regulated in Bmal1 −/− animals but only weakly affected in
Clock/Clock mutant mice as CLOCKΔ19 still retains its repressor function. These data predict that targeted disruption of the Clock gene to generate a null phenotype, which has not been reported to date, will result in alterations in transcription profiles similar to what we have observed in Bmal1 −/− animals.
What is the molecular mechanism of CRY1-dependent switch from transactivation to transrepression? One potential explanation for how CRY1 might affect CLOCK/BMAL1 function is that CRY1 might impact posttranslational modification of the CLOCK/BMAL1 complex (Kondratov et al., unpublished data). As we have previously demonstrated, posttranslational regulation of the CLOCK and BMAL1 proteins (including phosphorylation, cytoplasm/nuclear translocation and degradation) is coupled with the transcriptional activity of the complex (20) . Thus, posttranslational modifications of CLOCK/BMAL1 induced by CRY1 expression may result in a switch from transactivation to repression on the same promoter. Alternatively, it is possible that the functional activity of the complex depends on its composition, i.e., the CLOCK/BMAL1 complex displays activator properties, while the CLOCK/BMAL1/CRY1 complex functions as a repressor. Detailed studies of CLOCK and BMAL1 modifications and the in vivo kinetics of CLOCK/BMAL1 and CRY1 interaction will clarify whether either of these mechanisms is responsible for the repressor activity that we have observed. Importantly, in any possible scenario, BMAL1 (and presumably, CLOCK) functions as an active component of the repressor complex.
One of the important findings reported here is the ability of CLOCK/BMAL1/CRY1 complex to interfere with the activity of other, non-circadian, transcription factors to activate the same promoter, which is demonstrated on the example of N-MYC and ETS factors. While the inhibitory effect of the CLOCK/BMAL1/CRY1 complex on N-MYC transactivation might be explained by the competition for the same binding site, it cannot account for the effect on the ETS-dependent transactivation, since the ETS recognition site is different from the E-box and thus the observed repression cannot be explained by competition for specific DNA sequences. The exact molecular mechanism underlying the ability of the CLOCK/BMAL1/CRY1 complex to interfere with promoter activation by other transcription factors remains to be determined. Potential mechanisms include competition for cofactors or components of the basal transcriptional machinery, recruitment of an active repressor or regulation of chromatin modifications. It is even possible that the circadian repressor complex suppresses the activities of N-MYC and ETS through the two different mechanisms.
Although these questions remain to be answered, it is clear that the dual functional activity of the major circadian complex provides an effective mechanism for the global control of transcription. Thus, it may account for circadian control of responses to various external stimuli (stress, nutrients, light etc). It is well known that different types of cellular stress lead to induction of various transcription factors (i.e., p53, NFκB or AP1 induction by radiation (reviewed in (25, 26) ), induction of NFκB during the immune response (27) or HIF1α induction in response to low oxygen (28) . These factors, in turn, activate downstream transcriptional targets important for cell death or survival. Some of these stress-induced genes may be transcriptional targets of CLOCK/BMAL1, therefore, their induction in response to stress will occur only at those times of the day when CLOCK/BMAL1 is functioning as an activator and does not interfere with the functional activity of other transcription factors (schematically shown in Fig. 6A ). At the times when the circadian transcriptional complex acts as an active repressor, the induction of stressinduced clock-controlled genes will be either significantly attenuated or completely suppressed (Fig. 6B) . Therefore, the pattern of stress-induced gene expression will vary at different stages of the circadian cycle, which will result in daily variations in the organism's response. The identification of genes that are induced by stress in a time-dependent manner may ultimately allow clinicians to predict how a patient will react to existing genotoxic treatments, such as chemotherapy and radiation, and may lead to the development of improved treatments.
In summary, we have demonstrated here that the dual functional activity of the CLOCK/BMAL1 transcriptional complex represents an unusual mechanism for transcriptional control based on a switch from transcriptional activation to transcriptional repression. Full understanding of the molecular details of circadian repressor function will not only allow for adjustment of existing therapeutic regimens to more favorable times, but will also provide potential targets for rational pharmacological modulation of the circadian clock, which may result in improved therapeutic index. 
